Bibliographic Info
GuidelineGuidelines for the treatment of malaria
Year of Publication2015
Issuing InstitutionWorld Health Organization
Recommendation
Status
Maintained
Recommended in favor
Strong
Revised dose recommendation for dihydroartemisinin + piperaquine in young children: Children weighing <25kg treated with dihydroartemisinin + piperaquine should receive a minimum of 2.5 mg/kg bw per day of dihydroartemisinin and 20 mg/ kg bw per day of piperaquine daily for 3 days.
Notes and Remarks
- 1)Piperaquine prolongs the QT interval by approximately the same amount as chloroquine but by less than quinine.
- 2)It is not necessary to perform an electrocardiogram before prescribing dihydroartemisinin + piperaquine, but this ACT should not be used in patients with congenital QT prolongation or who have a clinical condition or are on medications that prolong the QT interval.
- 3)There has been no evidence of cardiotoxicity in large randomized trials or in extensive deployment.
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO guidelines for malaria, 16 February 2021.
Year2021
InstitutionWHO
Guideline
WHO guidelines for malaria, 13 July 2021.
Year2021
InstitutionWHO
Guideline
WHO guidelines for malaria, 18 February 2022.
Year2022
InstitutionWHO
Guideline
WHO guidelines for malaria, 31 March 2022.
Year2022
InstitutionWHO
Guideline
WHO guidelines for malaria, 3 June 2022.
Year2022
InstitutionWHO
Guideline
WHO guidelines for malaria, 25 November 2022.
Year2022
InstitutionWorld Health Organization
Guideline
WHO Guidelines for malaria, 14 March 2023
Year2023
InstitutionWHO